Stupp R, Mason WP, Bent van den MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352 (10): 987-996. 10.1056/NEJMoa043330.
Article
CAS
PubMed
Google Scholar
Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP, et al: In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res. 2004, 10 (16): 5595-5603. 10.1158/1078-0432.CCR-03-0392.
Article
CAS
PubMed
Google Scholar
Basu S, Rosenzweig KR, Youmell M, Price BD: The DNA-dependent protein kinase participates in the activation of NF kappa B following DNA damage. Biochem Biophys Res Commun. 1998, 247 (1): 79-83. 10.1006/bbrc.1998.8741.
Article
CAS
PubMed
Google Scholar
Manna SK, Aggarwal BB: Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol. 1998, 161 (6): 2873-2880.
CAS
PubMed
Google Scholar
Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V, Merville MP: Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol. 2000, 60 (8): 1085-1089. 10.1016/S0006-2952(00)00391-9.
Article
CAS
PubMed
Google Scholar
Hayashi S, Yamamoto M, Ueno Y, Ikeda K, Ohshima K, Soma G, Fukushima T: Expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1, and c-Myc in human astrocytomas. Neurol Med Chir (Tokyo). 2001, 41 (4): 187-195. 10.2176/nmc.41.187.
Article
CAS
Google Scholar
Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S, Kumanishi T: Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg. 2002, 96 (5): 909-917. 10.3171/jns.2002.96.5.0909.
Article
CAS
PubMed
Google Scholar
Wang H, Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN: Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest. 2004, 84 (8): 941-951. 10.1038/labinvest.3700123.
Article
CAS
PubMed
Google Scholar
Nagai S, Kurimoto M, Washiyama K, Hirashima Y, Kumanishi T, Endo S: Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines. J Neurooncol. 2005, 74 (2): 105-111. 10.1007/s11060-004-5757-1.
Article
CAS
PubMed
Google Scholar
Tsunoda K, Kitange G, Anda T, Shabani HK, Kaminogo M, Shibata S, Nagata I: Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion. Brain Tumor Pathol. 2005, 22 (2): 79-87. 10.1007/s10014-005-0186-1.
Article
CAS
PubMed
Google Scholar
Piret B, Schoonbroodt S, Piette J: The ATM protein is required for sustained activation of NF-kappaB following DNA damage. Oncogene. 1999, 18 (13): 2261-2271. 10.1038/sj.onc.1202541.
Article
CAS
PubMed
Google Scholar
Robe P, Nguyen-Khack MT, Lambert F, Lechanteur C, Jolois O, Ernst-Gengoux P, Rogister B, Bours V: Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystnader effect in malignant gliomas. International Journal of Oncology. 2007, 30 (1): 283-90.
CAS
PubMed
Google Scholar
Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI: Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. 2006, 24 (2): 274-287. 10.1200/JCO.2005.02.9405.
Article
CAS
PubMed
Google Scholar
Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998, 101 (5): 1163-1174. 10.1172/JCI992.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H: Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci. 2005, 25 (31): 7101-7110. 10.1523/JNEUROSCI.5258-04.2005.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lo M, Wang YZ, Gout PW: The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008, 215 (3): 593-602. 10.1002/jcp.21366.
Article
CAS
PubMed
Google Scholar
Rains CP, Noble S, Faulds D: Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs. 1995, 50 (1): 137-156. 10.2165/00003495-199550010-00009.
Article
CAS
PubMed
Google Scholar
Robe PA, Martin D, Albert A, Deprez M, Chariot A, Bours V: A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. BMC Cancer. 2006, 6 (1): 29-10.1186/1471-2407-6-29.
Article
PubMed
PubMed Central
Google Scholar
Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD: GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol. 2005, 7 (4): 425-434. 10.1215/S1152851705000554.
Article
PubMed
PubMed Central
Google Scholar
Macdonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990, 8 (7): 1277-1280.
CAS
PubMed
Google Scholar
Gering DNA, Kikinis R, Grimson W, Hata N, Everett P, Jolesz F, Wells W: An Integrated Visualization System for Surgical Planning and Guidance using Image Fusion and Interventional Imaging. Int Conf Med Image Comput Comput Assist Interv. 1999, 2: 11-
Google Scholar
Vlassenbroeck I, Califice S, Diserens A, Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou M, Renard I, Delorenzi M, et al: Validation of Real-Time MSP to Determine MGMT Promoter Methylation in Glioma. J Mol Diagn. 2008, 10: 6-10.2353/jmoldx.2008.070169.
Article
Google Scholar
Takahashi H, Ito S, Nagumo K, Kojima S, Umibe T, Hattori T: Salazosulfapyridine-induced encephalopathy with symmetrical lesions in the basal ganglia and thalami. Intern Med. 2006, 45 (15): 927-929. 10.2169/internalmedicine.45.1666.
Article
PubMed
Google Scholar
Mut SE, Kutlu G, Ucler S, Erdal A, Inan LE: Reversible encephalopathy due to sulfasalazine. Clin Neuropharmacol. 2008, 31 (6): 368-371. 10.1097/WNF.0b013e31817f125d.
Article
CAS
PubMed
Google Scholar
Schoonjans R, Mast A, Abeele Van den G, Dewilde D, Achten E, Van Maele V, Pauwels W: Sulfasalazine-associated encephalopathy in a patient with Crohn's disease. Am J Gastroenterol. 1993, 88 (10): 1759-1763.
CAS
PubMed
Google Scholar
Sevgi E, Yalcin G, Kansu T, Varli K: Drug induced intracranial hypertension associated with sulphasalazine treatment. Headache. 2008, 48 (2): 296-298.
Article
PubMed
Google Scholar
Correale J, Olsson T, Bjork J, Smedegard G, Hojeberg B, Link H: Sulfasalazine aggravates experimental autoimmune encephalomyelitis and causes an increase in the number of autoreactive T cells. J Neuroimmunol. 1991, 34 (2-3): 109-120. 10.1016/0165-5728(91)90120-V.
Article
CAS
PubMed
Google Scholar
Mehta D, Malik AB: Signaling mechanisms regulating endothelial permeability. Physiol Rev. 2006, 86 (1): 279-367. 10.1152/physrev.00012.2005.
Article
CAS
PubMed
Google Scholar
Hurst RD, Heales SJ, Dobbie MS, Barker JE, Clark JB: Decreased endothelial cell glutathione and increased sensitivity to oxidative stress in an in vitro blood-brain barrier model system. Brain Res. 1998, 802 (1-2): 232-240. 10.1016/S0006-8993(98)00634-9.
Article
CAS
PubMed
Google Scholar
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005, 352 (10): 997-1003. 10.1056/NEJMoa043331.
Article
CAS
PubMed
Google Scholar
Li A, Walling J, Kotliarov Y, Center A, Steed ME, Ahn SJ, Rosenblum M, Mikkelsen T, Zenklusen JC, Fine HA: Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res. 2008, 6 (1): 21-30. 10.1158/1541-7786.MCR-07-0280.
Article
CAS
PubMed
Google Scholar
Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, Carlin G, Huie MA, Cronstein BN: Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998, 101 (2): 295-300. 10.1172/JCI1554.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rathbone MP, Middlemiss PJ, Kim JK, Gysbers JW, DeForge SP, Smith RW, Hughes DW: Adenosine and its nucleotides stimulate proliferation of chick astrocytes and human astrocytoma cells. Neurosci Res. 1992, 13 (1): 1-17. 10.1016/0168-0102(92)90030-G.
Article
CAS
PubMed
Google Scholar
Olivier S, Robe P, Bours V: Can NF-kappaB be a target for novel and efficient anti-cancer agents?. Biochem Pharmacol. 2006, 72 (9): 1054-68. 10.1016/j.bcp.2006.07.023.
Article
CAS
PubMed
Google Scholar